Nektar Therapeutics (India) Pvt Ltd
Nektar Therapeutics is dedicated to creating new medicines that address serious medical needs by leveraging cutting-edge chemistry and biology. They focus on advancing therapies that modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer, with a mission to bring hope to patients worldwide.
Industries
Nr. of Employees
large (251-1000)
Nektar Therapeutics (India) Pvt Ltd
San Carlos, California, United States, North America
Products
IL-2 regulatory T cell stimulator (clinical-stage biologic)
A biologic designed to preferentially stimulate regulatory T cells via IL-2 pathway modulation; progressed into Phase 2 clinical studies for autoimmune indications.
IL-15 receptor agonist biologic (clinical-stage)
An IL-15 pathway agonist developed for immuno-oncology and hematologic malignancies; studied in combination with cell therapies and immune checkpoint inhibitors across multiple clinical trials.
PEG-modified hematopoietic colony-stimulating factor (preclinical)
A polyethylene glycol–modified colony-stimulating factor protein intended to alter PK/PD properties for therapeutic applications; currently in preclinical development.
Bivalent agonistic antibody targeting immune receptor (preclinical)
Engineered bivalent antibody agonist directed at an immune regulatory receptor for potential use in immunomodulatory indications; currently at preclinical stage.
Out-licensed technologies used in marketed biologics
Polymer-conjugation and related modification technologies licensed to third parties and applied in marketed therapeutic products.
IL-2 regulatory T cell stimulator (clinical-stage biologic)
A biologic designed to preferentially stimulate regulatory T cells via IL-2 pathway modulation; progressed into Phase 2 clinical studies for autoimmune indications.
IL-15 receptor agonist biologic (clinical-stage)
An IL-15 pathway agonist developed for immuno-oncology and hematologic malignancies; studied in combination with cell therapies and immune checkpoint inhibitors across multiple clinical trials.
PEG-modified hematopoietic colony-stimulating factor (preclinical)
A polyethylene glycol–modified colony-stimulating factor protein intended to alter PK/PD properties for therapeutic applications; currently in preclinical development.
Bivalent agonistic antibody targeting immune receptor (preclinical)
Engineered bivalent antibody agonist directed at an immune regulatory receptor for potential use in immunomodulatory indications; currently at preclinical stage.
Out-licensed technologies used in marketed biologics
Polymer-conjugation and related modification technologies licensed to third parties and applied in marketed therapeutic products.
Services
R&D collaborations and licensing
Collaborative discovery, licensing of molecules and technologies, and co-development arrangements with pharmaceutical and biotech partners.
Research platform access (targeting and molecule design)
Access to a research approach combining immunology target selection and polymer-chemistry design to create selective immunomodulatory therapeutics.
Clinical development collaborations
Cooperative clinical programs including investigator-sponsored trials and multi-site studies across Phase 1–3.
R&D collaborations and licensing
Collaborative discovery, licensing of molecules and technologies, and co-development arrangements with pharmaceutical and biotech partners.
Research platform access (targeting and molecule design)
Access to a research approach combining immunology target selection and polymer-chemistry design to create selective immunomodulatory therapeutics.
Clinical development collaborations
Cooperative clinical programs including investigator-sponsored trials and multi-site studies across Phase 1–3.
Expertise Areas
- Immunomodulating therapeutic development
- Autoimmune and inflammatory disease therapeutics
- Oncology immunotherapy and combination regimens
- Polymer-based biologic modification (PEGylation)
Key Technologies
- Polymer chemistry for biologics
- Polyethylene glycol (PEG) modification
- Cytokine-pathway modulation (e.g., IL-2, IL-15)
- Antibody engineering (bivalent agonists)